Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery

NACompletedINTERVENTIONAL
Timeline

Start Date

June 30, 1998

Study Completion Date

August 31, 2003

Conditions
Intestinal ObstructionDigestive System Surgical Procedures
Interventions
DEVICE

Seprafilm Bioresorbable Membrane

Trial Locations (21)

Unknown

Mayo Clinic, Scottsdale

Kaiser Permanente Medical Center, Los Angeles

USC School of Medicine, Los Angeles

Harbor UCLA, Torrence

Washington Hospital Center, Washington D.C.

Cleveland Clinic, Weston

Johns Hopkins Medical Center, Baltimore

Boston Medical Center, Boston

Brigham and Women's Hospital, Boston

Mayo Medical Center, Rochester

Colon & Rectal Surgery Associates, Saint Paul

Washington University School of Medicine, St Louis

Mount Sinai School of Medicine, New York

Duke University Medical Center, Durham

Cleveland Clinic, Cleveland

University of Texas Medical School, Houston

Mount Sinai Hospital, Toronto

University of Erlangen, Erlangen

University Hospital Nijmegen, Nijmegan

University of Hull, Hull

St. Mary's Hospital, London

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00130715 - Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery | Biotech Hunter | Biotech Hunter